Microglial glutamate release evoked by α-synuclein aggregates is prevented by dopamine

Glia. 2018 Nov;66(11):2353-2365. doi: 10.1002/glia.23472. Epub 2018 Nov 5.

Abstract

When activated, microglial cells have the potential not only to secrete typical proinflammatory mediators but also to release the neurotransmitter glutamate in amounts that may promote excitotoxicity. Here, we wished to determine the potential of the Parkinson's disease (PD) protein α-Synuclein (αS) to stimulate glutamate release using cultures of purified microglial cells. We established that glutamate release was robustly increased when microglial cultures were treated with fibrillary aggregates of αS but not with the native monomeric protein. Promotion of microglial glutamate release by αS aggregates (αSa) required concomitant engagement of TLR2 and P2X7 receptors. Downstream to cell surface receptors, the release process was mediated by activation of a signaling cascade sequentially involving phosphoinositide 3-kinase (PI3K) and NADPH oxidase, a superoxide-producing enzyme. Inhibition of the Xc- antiporter, a plasma membrane exchange system that imports extracellular l-cystine and exports intracellular glutamate, prevented the release of glutamate induced by αSa, indicating that system Xc- was the final effector element in the release process downstream to NADPH oxidase activation. Of interest, the stimulation of glutamate release by αSa was abrogated by dopamine through an antioxidant effect requiring D1 dopamine receptor activation and PI3K inhibition. Altogether, present data suggest that the activation of microglial cells by αSa may possibly result in a toxic build-up of extracellular glutamate contributing to excitotoxic stress in PD. The deficit in dopamine that characterizes this disorder may further aggravate this process in a vicious circle mechanism.

Keywords: Parkinson; glutamate; microglia; neuroinflammation; α-synuclein.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / analogs & derivatives
  • Adenosine Triphosphate / pharmacology
  • Animals
  • Animals, Newborn
  • Antibodies, Monoclonal / pharmacology
  • Carbon Isotopes / pharmacokinetics
  • Cells, Cultured
  • Cystine / pharmacokinetics
  • Dopamine / pharmacology*
  • Glutamic Acid / metabolism*
  • Humans
  • Lipopeptides / pharmacology
  • Lipopolysaccharides / pharmacology
  • Mice
  • Microglia / drug effects*
  • Microglia / ultrastructure
  • Platelet Aggregation Inhibitors / pharmacology
  • Protein Aggregates / drug effects*
  • Reactive Oxygen Species / metabolism
  • Signal Transduction / drug effects
  • Toll-Like Receptor 2 / immunology
  • alpha-Synuclein / metabolism*
  • alpha-Synuclein / pharmacology

Substances

  • Antibodies, Monoclonal
  • Carbon Isotopes
  • Lipopeptides
  • Lipopolysaccharides
  • Pam(3)CSK(4) peptide
  • Platelet Aggregation Inhibitors
  • Protein Aggregates
  • Reactive Oxygen Species
  • Tlr2 protein, mouse
  • Toll-Like Receptor 2
  • alpha-Synuclein
  • Glutamic Acid
  • Cystine
  • 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate
  • Adenosine Triphosphate
  • Dopamine